on BIOMERIEUX (EPA:BIM)
BioMérieux Gains U.S. FDA Clearance for Advanced Gastrointestinal Panels
On November 9, 2026, bioMérieux, a leader in in vitro diagnostics, announced the U.S. FDA 510(k) clearance of its BIOFIRE® FILMARRAY® Gastrointestinal 1.1 (GI1.1) Panel and the BIOFIRE® FILMARRAY® GI1.1 Panel Mid. These panels aim to enhance detection of 22 and 11 common gastroenteritis pathogens, respectively. The results are delivered within an hour, covering bacteria, viruses, and parasites from a single sample.
Gastroenteritis is a significant global health concern. Timely detection and diagnosis are crucial, especially for children and older adults. The updated panels include a redesigned norovirus assay and an improved Campylobacter detection, enhancing specificity and diagnostic confidence.
The panels, deployable globally, contribute to informed clinical decision-making and better patient management. They are intended for use on bioMérieux’s BIOFIRE® FILMARRAY® systems and signify a milestone in utilizing up-to-date diagnostic tools in healthcare settings.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOMERIEUX news